<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02897297</url>
  </required_header>
  <id_info>
    <org_study_id>OBENE</org_study_id>
    <nct_id>NCT02897297</nct_id>
  </id_info>
  <brief_title>Myeloproliferative Neoplastic Diseases Observatory From Brest</brief_title>
  <acronym>OBENE</acronym>
  <official_title>Observatoire Brestois Des Néoplasies Myéloprolifératives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients diagnosed or followed in Brest University Hospital for Philadelphia negative
      myeloproliferative neoplasms will be included in this observational study.

      Myeloproliferative neoplasms recorded included: polycythemia vera, essential Thrombocythemia
      and Primary Myelofibrosis.

      This is a not interventional study. Alive patients need to sign a non-opposition consent
      form.

      Patients will be followed until last news (death, change of reference centre...).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this retrospective and prospective study, clinical and biological data from diagnosis
      until last news will be recorded.

      Clinical data collected: patients and disease characteristics at the time of the diagnosis,
      disease and mutational status, cardio-vascular risk factors, history of thrombosis and
      cancer.

      Biological data collected: hemogram and bone marrow results if available. During the
      follow-up new data will be noted: treatment changes (reasons of change and type of drug),
      thrombotic events (localization, date and hemogram), phenotypic evolutions (type and date),
      death (date and etiology).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>10 years</time_frame>
    <description>occurrence of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of evolutions</measure>
    <time_frame>10 years</time_frame>
    <description>occurrence of transformation into polycythemia vera, secondary myelofibrosis, myelodysplastic syndrome or acute leukemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thromboses</measure>
    <time_frame>10 years</time_frame>
    <description>occurrence of arterial or venous thrombotic events</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Primary Myelofibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients followed for essentiel thrombocythemia, polycythemia vera or primary myelofibrosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with essentiel thrombocythemia, polycythemia vera or primary myelofibrosis

          -  Signature of the non-opposition consent form

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Ianotto</last_name>
    <role>Study Director</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe Ianotto</last_name>
    <email>jean-christophe.Ianotto@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe Ianotto, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Eric Lippert, MD-PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Delluc A, Lacut K, Pan-Petesch B, Galinat H, Lippert E, Ianotto JC. Statin exposure and thrombosis risk in patients with myeloproliferative neoplasms. Thromb Res. 2018 Jul;167:57-59. doi: 10.1016/j.thromres.2018.05.014. Epub 2018 May 16.</citation>
    <PMID>29787944</PMID>
  </results_reference>
  <results_reference>
    <citation>Mollard LM, Chauveau A, Boyer-Perrard F, Douet-Guilbert N, Houot R, Quintin-Roué I, Couturier MA, Dagorne A, Malou M, Le Calloch R, Luycx O, Thepot S, Hunault M, Guillerm G, Berthou C, Ugo V, Lippert É, Ianotto JC. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase. Leuk Lymphoma. 2018 Dec;59(12):2812-2820. doi: 10.1080/10428194.2018.1441408. Epub 2018 Apr 4.</citation>
    <PMID>29616837</PMID>
  </results_reference>
  <results_reference>
    <citation>Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, Boyer F, Conejero C, Fitoussi O, Riou J, Adiko D, Touati M, Chauzeix J, Viallard JF, Béné MC, Giraudier S, Ugo V, Lippert E. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol. 2018 Aug;93(4):E84-E86. doi: 10.1002/ajh.25014. Epub 2018 Jan 12.</citation>
    <PMID>29266414</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A, Dalbies F, Eveillard JR, Ugo V, Giraudier S, Guillerm G, Lippert E, Berthou C, Ianotto JC. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study). Haematologica. 2018 Apr;103(4):607-613. doi: 10.3324/haematol.2017.180448. Epub 2017 Dec 15.</citation>
    <PMID>29246923</PMID>
  </results_reference>
  <results_reference>
    <citation>Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica. 2018 Mar;103(3):438-446. doi: 10.3324/haematol.2017.181297. Epub 2017 Dec 7.</citation>
    <PMID>29217781</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahé K, Delluc A, Chauveau A, Castellant P, Mottier D, Dalbies F, Berthou C, Guillerm G, Lippert E, Ianotto JC. Incidence and impact of atrial arrhythmias on thrombotic events in MPNs. Ann Hematol. 2018 Jan;97(1):101-107. doi: 10.1007/s00277-017-3164-x. Epub 2017 Nov 21.</citation>
    <PMID>29164292</PMID>
  </results_reference>
  <results_reference>
    <citation>Ianotto JC, Couturier MA, Galinat H, Mottier D, Berthou C, Guillerm G, Lippert E, Delluc A. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol. 2017 Oct;106(4):517-521. doi: 10.1007/s12185-017-2282-5. Epub 2017 Jun 16.</citation>
    <PMID>28623609</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Clech L, Sakka M, Meskar A, Kerspern H, Eveillard JR, Berthou C, Buors C, Lippert E, Guillerm G, Quintin-Roué I, Carré JL, Ianotto JC. The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes. Leuk Lymphoma. 2017 Nov;58(11):2582-2587. doi: 10.1080/10428194.2017.1312380. Epub 2017 May 9.</citation>
    <PMID>28482711</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Gall-Ianotto C, Brenaut E, Gouillou M, Lacut K, Nowak E, Tempescul A, Berthou C, Ugo V, Carré JL, Misery L, Ianotto JC. Clinical characteristics of aquagenic pruritus in patients with myeloproliferative neoplasms. Br J Dermatol. 2017 Jan;176(1):255-258. doi: 10.1111/bjd.14809. Epub 2016 Dec 22.</citation>
    <PMID>27291777</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

